EUCTR2020-004583-26-IT进行中（未招募）1 期
A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD1d-positive chronic lymphocytic leukemia, multiplemyeloma or acute myeloid leukemia - LAVA
AVA Therapeutics NV0 个研究点目标入组 222 人开始时间: 2021年6月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 222
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient must be 18 years of age inclusive or above, at the time of signing the informed consent
- •2. Confirmed tumor cell CD1d positivity/expression
- •3. Patients with documented diagnosis of CLL, MM, or AML who have failed to respond to or who have relapsed after prior therapy and are not amenable to standard treatments or for whom no standard treatments are available. Patients may have undergone prior cell therapy
- •CLL/ SL) patients:
- •-Proven disease by the presence of CD5+CD19+CD23+ clonal B cells in blood, bone marrow and/or lymph nodes.
- •-Patients should meet criteria for requiring therapy (the most recent iwCLL guidelines (39)) and must have measurable disease (measurable lesion > 1.5 cm diameter in at least one dimension) and/or lymphocytosis
- •-Patients must have failed at least one line of targeted therapy (ibrutinib or venetoclax or similar) and not be amenable to- or for whom no further standard treatment is available
- •-Patients with Richter’s transformation can be included in Part 1 of the trial but not in Part 2 of the trial
- •MM patients:
- •-Documented diagnosis of MM and measurable disease
- •-Documented progression or refractory multiple myeloma as per the IMWG uniform response criteria following =3 prior regimens that include at least one immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 monoclonal antibody in any order.
- •AML patients:
- •-Patients with relapsed/refractory AML
- •-Patients with relapsed/refractory AML after at least one prior AML therapy.
- •4. Males or non-pregnant, non-breastfeeding females who are:
- •a. Surgically sterile
- •b. Female of childbearing potential with a negative pregnancy test prior to first dosing and compliant with a highly effective contraceptive regimen from signing of the ICF through 90 days after the last IMP administration. Abstinence is not considered an adequate contraceptive regimen.
- •c. Female, postmenopausal defined as continuous amenorrhea for at least 12 consecutive months without an alternative medical cause and a serum follicle-stimulating hormone (FSH) measurement of > 40 IU/L).
- •d. Male, compliant with an effective contraceptive regimen (i.e., use of male condom with female partner and assuring use of an additional highly effective contraceptive method with a failure rate of <1% per year when having sexual intercourse with a woman of childbearing potential who is not currently pregnant following from signing of the ICF through 90 days after the last IMP administration; refer to Appendix 4, Section 13.4 for more details) from signing of the ICF through 90 days after the last IMP administration). Abstinence is not considered an adequate contraceptive regimen.
- •e. Male, refraining from donating sperm following from signing of the ICF through 90 days after the last IMP administration.
- •5. Predicted life-expectancy of = 3 months
- •6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •7. Adequate renal function (estimated glomerular filtration rate [eGFR] per local laboratory > 40 mL/min/1.73m2), hepatic function [(total bilirubin = 2 times upper limit of normal (ULN), unless in patients with known Gilbert’s syndrome who must have total bilirubin = 3 times ULN; AST and ALT = 3.0 times ULN] and hematological function (neutrophils = 1 x109/L; platelet count = 75x109/L, unless due to bone marrow tumor infiltration, in which case it must be = 50x109/L)
- •8. Capable of giving signed and dated informed consent prior to initiation of any trial-related procedure that is not conside
排除标准
- •1. Prior allogeneic bone marrow transplant as long as the patient still has active acute or chronic graft versus host disease requiring >10 mg prednisone or equivalent corticosteroids.
- •2. Concomitant malignancies except carcinoma in situ, basal or squamous cell skin carcinoma. Patients who had no evidence of disease from another primary cancer for 2 or more years are allowed to participate in the trial. Localized non-metastatic prostate cancer, not requiring systemic treatment, and for which no local treatment is planned, is allowed.
- •3. Uncontrolled or severe intercurrent medical condition.
- •4. Known uncontrolled central nervous system involvement.
- •5. Patient has any active-, uncontrolled-, or suspected infection.
- •6. A significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this trial.
- •7. Unstable cardiovascular function defined as: (a) symptomatic ischemia, or (b) uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on antiarrhythmic agents are excluded; 1st degree atrioventricular block or asymptomatic left anterior fascicular block/right bundle branch block (left anterior fascicular block /right bundle branch block) will not be excluded), or (c) congestive heart failure New York Heart Association Class = 3, or (d) myocardial infarction within 3 months.
- •8. Previous treatment with radiotherapy, immunotherapy, or chemotherapy in the 2 weeks prior to initial IMP administration.
- •9. Previous treatment with biological therapy or with an investigational product in the 4 weeks prior to initial IMP administration.
- •10. Previous treatment with an aminobisphosphonate IV (e.g., ibandronate, pamidronate, zoledronate etc) within 4 weeks prior to initial IMP.
- •11. Previous treatment of any systemic immunosuppressant within 2 weeks prior to initial IMP administration, with the exception of systemic corticosteroid use up to oral dose of 10 mg prednisolone daily (or equivalent for other steroids).
- •12. Previous treatment with live or live attenuated vaccines within 2 weeks prior to initial IMP administration. Other (new) types of vaccines need to be evaluated as to their mode of action.
- •13. Known non-CLL/MM/AML related pre-existing clinically relevant immunodeficiency disorders.
- •14. Positive serological testing for Human Immunodeficiency Virus (HIV) antibody, hepatitis B surface antigen [HBsAg] and hepatitis B core antibody (anti-HBc) negative, and hepatitis C virus antibody. Patients who are positive for anti-HBc or hepatitis C antibody may be included if they have a negative PCR within 6 weeks prior to initial IMP administration. Those who are PCR positive will be excluded.
- •15. Known allergies, hypersensitivity, or intolerance to the excipients of the IMP.
- •16. Major surgery within 4 weeks of initial IMP administration or planned surgery during the time the patient is expected to participate in the trial.
- •17. Known ongoing drug and alcohol abuse in the opinion of the investigator.
研究者
相似试验
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaCD1d-positive relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-ESAVA Therapeutics B.V.102
招募中
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaRelapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-FRAVA Therapeutics B.V.102
进行中（未招募）
1 期
A dose escalation trial to assess the safety and tolerability of multiple doses of the LAVA-051 antibody in patients with chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiaRelapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)EUCTR2020-004583-26-NLAVA Therapeutics N.V.114
招募中
不适用
A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma or acute myeloid leukemiamyeloma10024324leukemiaNL-OMON51940AVA Therapeutics BV20
招募中
不适用
A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell engager, alone or with low dose interleukin-2 or Pembrolizumab, in patients with therapy refractory metastatic castration resistant prostate cancerProstate cancerNL-OMON56169AVA Therapeutics NV42